RXi Remains 'Committed and Focused' on RNAi Despite Broadened Focus
April 07, 2011
RXi Remains 'Committed and Focused' on RNAi Despite Broadened Focus
RXi's pending acquisition of Apthera will also enable the company to explore the combination of its RNAi technologies with Apthera's peptide know-how, RXi's CEO said.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- SEC Filing Indicates RXi Will Trade as 'Penny Stock,' Face Alnylam IP Challenge
December 15, 2011 / Gene Silencing News - RXi Looks to Raise $10.9M in Public Offering; Needs More than $2M to Move Cancer Rx into Phase III
April 21, 2011 / Gene Silencing News - RXi Closes Acquisition of Apthera
April 14, 2011 / Gene Silencing News - After Acquiring Opko Assets, RXi Aims to Resurrect Former Phase III AMD Drug
June 13, 2013 / Gene Silencing News - Phase I Data Shows RXi Anti-Scarring Drug Safe, Well-tolerated
June 6, 2013 / Gene Silencing News